EmstoPA
Reversal of tPA-induced severe bleeding (e.g., intracranial hemorrhage)
Pre-clinicalActive
Key Facts
Indication
Reversal of tPA-induced severe bleeding (e.g., intracranial hemorrhage)
Phase
Pre-clinical
Status
Active
Company
About Emstopa
Emstopa is a preclinical-stage biotech addressing a critical unmet need in emergency medicine: uncontrolled bleeding caused by the thrombolytic drug tPA. The company is developing EmstoPA, a targeted antibody reversal agent that could save lives and reduce disability by allowing safer use of tPA. Led by a small, experienced team with deep expertise in cardiovascular drugs and biologics, the company is positioned to develop the first specific antidote for tPA-related hemorrhage. If successful, EmstoPA could expand the therapeutic window and usage of tPA, a cornerstone treatment for ischemic events.
View full company profile